Previous studies have shown that the dysregulated expression of EZH2, one of the three core components of PRC2 (EZH2, SUZ12, and EED), could be a biomarker in diverse cancers, such as lung cancer, gastric cancer, hepatocellular carcinoma and cervical cancer [17–20]. Here, EZH2 is linked to cervical carcinoma.